Sushil Sharma - Böcker

This book introduces charnolophagy (CP) as energy-driven, lysosomal-dependent mitochondrial inclusion-specific pleomorphic Charnoly body (CB) autophagy (ATG) involving free radical-induced Ca2+ dyshomeostasis, ΔΨ collapse, and ATP depletion in congenital diseases, pressure ulcers, metabolic diseases, hepatic diseases, diabetes, obesity, inflammatory diseases, musculoskeletal diseases, sarcopenia, cachexia, respiratory diseases, gastrointestinal diseases, hyperlipidemia, skin and hair diseases, pulmonary diseases, cardiovascular diseases, renal diseases, sepsis-induced multi-organ failure, reproductive diseases, inflammatory diseases, ophthalmic diseases, neurodegenerative diseases, drug addiction, aging, microbial (including COVID-19) infections, and belligerent malignancies implicated in early morbidity and mortality and disease-specific spatiotemporal, targeted, safe, and effective evidence-based personalized theranostic charnolopharmacotherapeutics to cure them. Basic DRESS and GELS principles, nanoparticles to cure chronic multidrug-resistant (MDR) diseases, antioxidants as free radical scavengers, CB antagonists, CP regulators, and CS stabilizers to curb CB molecular pathogenesis (CBMP) are described for better quality of life and longevity. Specific guidelines for environmental protection and preservation of zoological and botanical species at the verge of extinction, Triple "I" Hypothesis for mitochondrial quality control, and transcriptional regulation of CSexR and CSendoR to cure chronic diseases are presented. Novel CP index is introduced to evaluate MDR malignancies and other chronic diseases. WHO, CDC, FDA, NIH, policy planners, cosmetologists, trichologists, players, athletes, dancers, wrestlers, equestrians, young women, aging population, toxicologists, environmental protectionists, pharmaceutical industry, biomedical scientists, researchers, medical students, physicians, nurses, paramedical professionals, and global audience will be interested in this interesting book to prevent pandemics and raise healthcare awareness.

This book introduces charnolophagy (CP) as energy-driven, lysosomal-dependent mitochondrial inclusion-specific pleomorphic Charnoly body (CB) autophagy (ATG) involving free radical-induced Ca2+ dyshomeostasis, ΔΨ collapse, and ATP depletion in congenital diseases, pressure ulcers, metabolic diseases, hepatic diseases, diabetes, obesity, inflammatory diseases, musculoskeletal diseases, sarcopenia, cachexia, respiratory diseases, gastrointestinal diseases, hyperlipidemia, skin and hair diseases, pulmonary diseases, cardiovascular diseases, renal diseases, sepsis-induced multi-organ failure, reproductive diseases, inflammatory diseases, ophthalmic diseases, neurodegenerative diseases, drug addiction, aging, microbial (including COVID-19) infections, and belligerent malignancies implicated in early morbidity and mortality and disease-specific spatiotemporal, targeted, safe, and effective evidence-based personalized theranostic charnolopharmacotherapeutics to cure them. Basic DRESS and GELS principles, nanoparticles to cure chronic multidrug-resistant (MDR) diseases, antioxidants as free radical scavengers, CB antagonists, CP regulators, and CS stabilizers to curb CB molecular pathogenesis (CBMP) are described for better quality of life and longevity. Specific guidelines for environmental protection and preservation of zoological and botanical species at the verge of extinction, Triple "I" Hypothesis for mitochondrial quality control, and transcriptional regulation of CSexR and CSendoR to cure chronic diseases are presented. Novel CP index is introduced to evaluate MDR malignancies and other chronic diseases. WHO, CDC, FDA, NIH, policy planners, cosmetologists, trichologists, players, athletes, dancers, wrestlers, equestrians, young women, aging population, toxicologists, environmental protectionists, pharmaceutical industry, biomedical scientists, researchers, medical students, physicians, nurses, paramedical professionals, and global audience will be interested in this interesting book to prevent pandemics and raise healthcare awareness.

Diversified physicochemical injuries trigger Charnoly body (CB) formation as pleomorphic, electron-dense, multi-lamellar stacks of nonfunctional mitochondrial membranes in the most vulnerable cell. Free radicals induce downregulation of mitochondrial DNA, microRNA, AgNOR, and epigenetics to trigger CB molecular pathogenesis. CB is eliminated by energy (ATP)-driven lysosome-dependent charnolophagy as a basic molecular mechanism of intracellular detoxification to prevent acute and chronic diseases. Accumulation of CB at the junction of axon hillock and charnolosome (CS) at the synapses causes cognitive impairments; whereas, nonspecific induction of CB causes GIT stress, myelosuppression, alopecia, neurotoxicity, cardiotoxicity, and infertility in multidrug-resistant malignancies. Hence, stem cell-specific CB, charnolophagy, and CS agonists/antagonists are introduced as novel charnolopharmacotherapeutics for the successful treatment of cardiovascular diseases, neurodegenerative diseases, infectious diseases, drug addiction, and cancer. Nanoparticles to improve drug delivery, CS exocytosis, and disease-specific spatiotemporal charnolosomics employing correlative and combinatorial bioinformatics boost mitochondrial bioenergetics through balanced diet, exercise, and antioxidants. The book will be of interest to medical scientists and practitioners.

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases.The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.

Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular levelConsiders the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseasesPresents future perspectives of the charnolosome in personalized nanotheranostics

Diversified physicochemical injuries trigger Charnoly body (CB) formation as pleomorphic, electron-dense, multi-lamellar stacks of nonfunctional mitochondrial membranes in the most vulnerable cell. Free radicals induce downregulation of mitochondrial DNA, microRNA, AgNOR, and epigenetics to trigger CB molecular pathogenesis. CB is eliminated by energy (ATP)-driven lysosome-dependent charnolophagy as a basic molecular mechanism of intracellular detoxification to prevent acute and chronic diseases. Accumulation of CB at the junction of axon hillock and charnolosome (CS) at the synapses causes cognitive impairments; whereas, nonspecific induction of CB causes GIT stress, myelosuppression, alopecia, neurotoxicity, cardiotoxicity, and infertility in multidrug-resistant malignancies. Hence, stem cell-specific CB, charnolophagy, and CS agonists/antagonists are introduced as novel charnolopharmacotherapeutics for the successful treatment of cardiovascular diseases, neurodegenerative diseases, infectious diseases, drug addiction, and cancer. Nanoparticles to improve drug delivery, CS exocytosis, and disease-specific spatiotemporal charnolosomics employing correlative and combinatorial bioinformatics boost mitochondrial bioenergetics through balanced diet, exercise, and antioxidants. The book will be of interest to medical scientists and practitioners.

I3E 2009 was held in Nancy, France, during September 23–25, hosted by Nancy University and INRIA Grand-Est at LORIA. The conference provided scientists andpractitionersofacademia,industryandgovernmentwithaforumwherethey presented their latest ?ndings concerning application of e-business, e-services and e-society, and the underlying technology to support these applications. The 9th IFIP Conference on e-Business, e-Services and e-Society, sponsored by IFIP WG 6.1. of Technical Committees TC6 in cooperation with TC11, and TC8 represents the continuation of previous events held in Zurich (Switzerland) in 2001, Lisbon (Portugal) in 2002, Sao Paulo (Brazil) in 2003, Toulouse (France) in 2004, Poznan (Poland) in 2005, Turku (Finland) in 2006, Wuhan (China) in 2007 and Tokyo (Japan) in 2008. The call for papers attracted papers from 31 countries from the ?ve con- nents. As a result, the I3E 2009 programo?ered 12 sessions of full-paper pres- tations. The 31 selected papers cover a wide and important variety of issues in e-Business,e-servicesande-society,including security,trust,andprivacy,ethical and societal issues, business organization, provision of services as software and software as services, and others. Extended versions of selected papers submitted to I3E 2009 will be published in the International Journal of e-Adoption and in AIS Transactions on Enterprise Systems. In addition, a 500-euros prize was awarded to the authors of the best paper selected by the Program Comm- tee. We thank all authors who submitted their papers, the Program Committee members and external reviewers for their excellent work.